Menu
GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Unit (HTAU)
    • HTA Philippines Annual Report
      • 2020 Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Issuances
  • Assessments
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Contact Us
    • Careers
    • Call for Interested Parties
    • Topic Nomination
  • AUXILIARY MENU
  • GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Unit (HTAU)
    • HTA Philippines Annual Report
      • 2020 Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Issuances
  • Assessments
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Contact Us
    • Careers
    • Call for Interested Parties
    • Topic Nomination

COVID-19 Investigational Drugs

Remdesivir, Tocilizumab, Baricitinib, and Favipiravir

Dexamethasone

Favipiravir

Cycloferon

209145
Users Today : 538
This Month : 21442
Total Users : 209145
Your IP Address : 18.207.238.146
Philippine Standard Time:
✕

Philippine Society of Microbiology and Infectious Diseases (PSMID) releases Philippine COVID-19 Living Recommendations

View the document on their website: https://www.psmid.org/philippine-covid-19-living-recommendations/